Reagan Wetherill, PhD, LCP
Additional Information & Contact: Dept. of Psychiatry link
Dr. Reagan Wetherill is an Assistant Professor of Psychiatry and Licensed Clinical Psychologist at the Perelman School of Medicine at the University of Pennsylvania. She received her Ph.D. in clinical psychology at the University of Texas at Austin where she conducted alcohol administration and neuroimaging research to understand the effects of alcohol on memory processes and alcohol-induced blackouts. She completed her clinical psychology internship at the University of California, San Diego and VA San Diego and completed her postdoctoral fellowship with Dr. Susan Tapert. After completing her postdoctoral training, she joined the Center for Studies of Addiction and was appointed to faculty in 2013. Dr. Wetherill directs a translational program of research focused on improving treatment outcomes for addictive disorders, with an emphasis on women and, more recently, using positron emission tomography (PET) to gain insights into the effects of alcohol and substance use on oxidative stress/inflammation. Dr. Wetherill serves as a Field Editor for Alcoholism: Clinical and Experimental Research, a Consultant for the Title IX Office at UPenn and the Department of Defense, and as a grant reviewer for the National Institutes of Health.
Grants & Funding
National Institute on Drug Abuse - R01 DA040670 (Wetherill): Influence of the natural hormonal milieu on perfusion fMRI smoking cue responses
National Heart, Lung, and Blood Institute - R21 HL144673 (Wetherill): Using PET to measure pulmonary oxidative stress in e-cigarette users
National Institute on Alcohol Abuse and Alcoholism - K23 AA023984 (Wetherill): Effectiveness of topiramate: characterizing individual differences
Department of Human Health and Services - R44 GM130195 (Schleisman): BrainAware: interactive digital psychoeducation for adolescents and young adults with substance use disorders (Site PI)
Wetherill RR, Spilka N, Jagannathan K, Morris P, Romer D, Pond T, Lynch KG, Franklin TR, Kranzler HR. Effects of topiramate on neural responses to alcohol use in treatment-seeking individuals with alcohol use disorder: preliminary findings from a randomized, placebo-controlled trial. Neuropsychopharmacol. 2021. https://doi.org/10.1038/s41386-021-00968-w
Aydogan G, Daviet R, Karlsson Linner R, Hare TA, Kable JW, Kranzler HR, Wetherill RR, Ruff CC, Koellinger PD, BIG BEAR Consortium, Nave G. Genetic underpinnings of risky behavior relate to altered neuroanatomy. Nat Human Behav. 2021. https://doi.org/10.1038/s41562-020-01027-y
Ely AV, Jagannathan K, Hager N, Ketcherside A, Franklin TR, Wetherill RR. Double jeopardy: comorbid obesity and cigarette smoking are linked to neurobiological alterations in inhibitory control during smoking cue exposure. Addict Biol. 2020 25(2):e12750.
Ketcherside A, Jagannathan K, Doliu S, Hager N, Spilka N, Nutor C, Rao H, Franklin TR, Wetherill RR. Baclofen-induced changes in the resting brain modulate smoking cue reactivity: a double-blind placebo-controlled functional magnetic resonance imaging study in cigarette smokers. Clin Psychopharmacol Neurosci. 2020 18(2):289-302.
Wetherill RR, Rao H, Hager N, Wang J, Franklin TR, Fan Y. Classifying and characterizing nicotine use disorder with high accuracy using machine learning and resting-state fMRI. Addict Biol. 2019 24(4):811-821.
Back to Top